PepGen Inc. is a pharmaceutical company based in the United States, specializing in developing advanced oligonucleotide therapeutics for severe neuromuscular and neurologic diseases. With an ESG score of 29.9, PepGen Inc. is considered to have a medium risk assessment. The company's Enhanced Delivery Oligonucleotide platform aims to enhance the effectiveness of oligonucleotide therapies by improving tissue penetration, cellular uptake, and nuclear delivery. Their pipeline includes products such as PGN-EDO51, PGN-EDODM1, PGN-EDO53, and PGN-EDO45.